Latest Period
Q4 2025
- Info
- Insider Trading
- Financials
- Holders
Security Snapshot
Mirum Pharmaceuticals, Inc. - Common Stock (MIRM) Institutional Ownership
CUSIP: 604749101
13F Institutional Holders and Ownership History from Q3 2019 to Q1 2026
Institutions Reporting
278
Shares (Excl. Options)
61,029,942
Price
$78.99
Save this security page for your next review
Keep this CUSIP in your watchlists so you can revisit quarter changes from one place.
- Type / Class
- Equity / Common Stock
- Symbol
- MIRM on Nasdaq
- Shares outstanding
- 51,400,915
- Price per share
- $92.38
- All holders as of 31 Dec 2025
- Q4 2025
- Total 13F shares
- 61,029,942
- Total reported value
- $4,820,614,496
- % of total 13F portfolios
- 0.01%
- Share change
- +3,560,112
- Value change
- +$288,257,792
- Number of holders
- 278
- Price from insider filings
- $92.38
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors
Quick Takeaways
- MIRM - Mirum Pharmaceuticals, Inc. - Common Stock is tracked under CUSIP 604749101.
- 278 institutions reported positions in Q4 2025.
- 4 significant owners is listed from Schedule 13D/13G reporting.
What Changed
- Holder count moved from 278 to 32 between Q4 2025 and Q1 2026.
- Reported value moved from $4,820,614,496 to $24,775,466.
Why This Matters
- You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
- 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.
Source Evidence
Source: SEC Form 13F
Open SEC Evidence
Latest holder context comes from 278 institutions filings for Q4 2025.
Investment Quick Answers
What is CUSIP 604749101?
CUSIP 604749101 identifies MIRM - Mirum Pharmaceuticals, Inc. - Common Stock in SEC 13F datasets.
Where can I see the latest institutional holders?
Review the Q4 2025 holders report and the ownership history table below.
Next ownership checks
Use the next link that matches the question you still need to answer about this security.
- Latest 13F filings when you want to inspect fresh institutional portfolio moves.
- Latest Schedule 13D/13G reports when you need large-owner changes outside the 13F cycle.
- All institutional ownership pages to compare this security with other holder-history pages.
Recent Quarterly Holder Reports
Open recent reporting periods for CUSIP 604749101:
Significant Owners of Mirum Pharmaceuticals, Inc. - Common Stock (MIRM) based on Schedule 13D/G filings
| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| JANUS HENDERSON GROUP PLC | 12% | +11% | $479,098,679 | +$48,995,048 | 6,065,308 | +11% | JANUS HENDERSON GROUP PLC | 31 Dec 2025 |
| Frazier Life Sciences IX, L.P. | 6.8% | -8.6% | $324,522,832 | +$29,477,804 | 4,108,404 | +10% | Patrick J. Heron | 23 Jan 2026 |
| EVENTIDE ASSET MANAGEMENT, LLC | 4.1% | -27% | $165,372,042 | -$40,549,990 | 2,093,582 | -20% | Eventide Asset Management, LLC | 31 Dec 2025 |
| BIOTECHNOLOGY VALUE FUND L P | 3% | $109,619,710 | 1,495,290 | BVF PARTNERS L P/IL | 30 Sep 2025 |
As of 31 Dec 2025, 278 institutional investors reported holding 61,029,942 shares of Mirum Pharmaceuticals, Inc. - Common Stock (MIRM). This represents 119% of the company’s total 51,400,915 outstanding shares.
Top 25 Institutional Shareholders
The largest institutional shareholders of Mirum Pharmaceuticals, Inc. - Common Stock (MIRM) together control 79% of the company’s outstanding shares — a level of ownership often associated with strong institutional conviction and long‑term capital commitment.
| Institution | Ownership % | Shares Held | Share Change % | Portfolio % | Holdings Value |
|---|---|---|---|---|---|
| Frazier Life Sciences Management, L.P. | 13% | 6,795,121 | 0% | 14% | $536,746,608 |
| JANUS HENDERSON GROUP PLC | 12% | 6,065,308 | +21% | 0.21% | $479,050,121 |
| BlackRock, Inc. | 7.1% | 3,645,286 | +1.2% | 0% | $287,941,139 |
| VANGUARD GROUP INC | 5.1% | 2,596,089 | +2% | 0% | $205,065,069 |
| STATE STREET CORP | 4.2% | 2,143,992 | +59% | 0.01% | $169,353,928 |
| EVENTIDE ASSET MANAGEMENT, LLC | 4.1% | 2,093,582 | -17% | 2.6% | $165,370,112 |
| BVF INC/IL | 2.9% | 1,495,290 | 0% | 4% | $118,112,957 |
| PRICE T ROWE ASSOCIATES INC /MD/ | 2.8% | 1,420,375 | +11% | 0.01% | $112,196,000 |
| NOVO HOLDINGS A/S | 2.5% | 1,264,028 | 0% | 7.8% | $99,845,572 |
| WELLINGTON MANAGEMENT GROUP LLP | 2.4% | 1,237,830 | +57% | 0.02% | $97,776,191 |
| TANG CAPITAL MANAGEMENT LLC | 2.4% | 1,236,027 | 0% | 4.8% | $97,633,773 |
| GEODE CAPITAL MANAGEMENT, LLC | 2.1% | 1,062,926 | +5.2% | 0.01% | $83,975,140 |
| D. E. Shaw & Co., Inc. | 1.8% | 948,161 | +2.7% | 0.06% | $74,895,237 |
| Clearbridge Investments, LLC | 1.7% | 865,967 | -14% | 0.05% | $68,402,733 |
| CITADEL ADVISORS LLC | 1.6% | 840,220 | -19% | 0.05% | $66,368,978 |
| Polar Capital Holdings Plc | 1.5% | 793,642 | -3.3% | 0.29% | $62,689,782 |
| Rock Springs Capital Management LP | 1.5% | 762,294 | +0.15% | 3.1% | $60,213,603 |
| GOLDMAN SACHS GROUP INC | 1.4% | 724,317 | +61% | 0.01% | $57,213,800 |
| BANK OF AMERICA CORP /DE/ | 1.4% | 713,452 | +83% | 0% | $56,355,574 |
| BNP PARIBAS FINANCIAL MARKETS | 1.3% | 655,778 | 0% | 0.03% | $51,799,904 |
| FRANKLIN RESOURCES INC | 1.3% | 650,715 | +8.2% | 0.01% | $51,399,978 |
| FMR LLC | 1.3% | 646,466 | +0.98% | 0% | $51,064,384 |
| LORD, ABBETT & CO. LLC | 1.1% | 579,983 | -12% | 0.14% | $45,813,000 |
| Pictet Asset Management Holding SA | 1.1% | 577,274 | +6.7% | 0.04% | $45,598,873 |
| Soleus Capital Management, L.P. | 1.1% | 573,614 | +286% | 1.9% | $45,309,770 |
Institutional Holders of Mirum Pharmaceuticals, Inc. - Common Stock (MIRM) across Reporting Periods
| Period | Reported Shares, Excl. Options | Value, Excl. Options | Value Change | Price (Median) | Investors |
|---|---|---|---|---|---|
| 2026 Q1 | 268,069 | $24,775,466 | -$963,366 | $92.38 | 32 |
| 2025 Q4 | 61,029,942 | $4,820,614,496 | +$288,257,792 | $78.99 | 278 |
| 2025 Q3 | 57,251,922 | $4,197,137,135 | +$132,883,151 | $73.31 | 268 |
| 2025 Q2 | 55,393,029 | $2,819,019,204 | +$70,434,976 | $50.89 | 211 |
| 2025 Q1 | 54,142,705 | $2,443,759,313 | +$49,081,267 | $45.05 | 213 |
| 2024 Q4 | 52,986,109 | $2,190,964,431 | -$26,045,809 | $41.35 | 204 |
| 2024 Q3 | 53,301,609 | $2,079,251,226 | -$2,890,149 | $39.00 | 176 |
| 2024 Q2 | 53,362,791 | $1,824,471,702 | +$17,964,526 | $34.19 | 157 |
| 2024 Q1 | 53,243,448 | $1,337,601,222 | +$70,337,692 | $25.12 | 167 |
| 2023 Q4 | 50,259,606 | $1,483,847,413 | +$1,676,068 | $29.52 | 184 |
| 2023 Q3 | 48,930,333 | $1,545,592,030 | +$398,674,334 | $31.60 | 156 |
| 2023 Q2 | 36,937,639 | $955,518,729 | +$63,103,719 | $25.87 | 143 |
| 2023 Q1 | 34,669,406 | $832,753,531 | +$33,992,984 | $24.02 | 114 |
| 2022 Q4 | 33,331,988 | $650,146,380 | -$12,725,497 | $19.50 | 101 |
| 2022 Q3 | 33,748,714 | $709,089,633 | +$93,197,315 | $21.01 | 107 |
| 2022 Q2 | 29,289,263 | $568,434,366 | +$47,575,699 | $19.46 | 104 |
| 2022 Q1 | 26,813,353 | $590,437,915 | -$6,195,298 | $22.02 | 99 |
| 2021 Q4 | 22,891,220 | $365,087,000 | +$18,990,411 | $15.95 | 81 |
| 2021 Q3 | 21,414,209 | $426,514,254 | +$2,080,056 | $19.92 | 69 |
| 2021 Q2 | 21,482,092 | $371,413,185 | +$642,669 | $17.29 | 66 |
| 2021 Q1 | 21,451,984 | $425,174,000 | -$8,433,468 | $19.82 | 60 |
| 2020 Q4 | 22,010,623 | $384,380,000 | +$52,268,047 | $17.46 | 71 |
| 2020 Q3 | 18,743,135 | $361,180,000 | -$1,290,295 | $19.27 | 50 |
| 2020 Q2 | 18,808,446 | $366,015,000 | +$8,936,163 | $19.46 | 57 |
| 2020 Q1 | 18,603,225 | $260,445,000 | +$32,083,278 | $14.00 | 43 |
| 2019 Q4 | 16,248,910 | $398,421,000 | +$12,819,124 | $24.52 | 39 |
| 2019 Q3 | 16,487,274 | $165,856,000 | +$165,755,000 | $10.06 | 38 |